Treatment of Cannabis Use Disorder: Current Science and Future Outlook
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
Cannabis is the most commonly used illicit substance in the United States. Rates of cannabis use and cannabis use disorder (CUD) have increased in the past decade, paralleling changes in the legal and political climate favoring legalization. Almost 20 million people 12 years or older report past‐month cannabis use, and 8 million report daily or near‐daily use. Concurrently, the perception that cannabis use poses a significant risk of negative consequences has decreased. Contrary to this perception, heavy cannabis use is associated with cognitive impairment, increased risk for psychotic disorders and other mental health problems, lower education attainment, and unemployment. Clinical trials of various treatments for CUD have likewise increased, focusing primarily on psychotherapy treatments, specifically motivational enhancement therapy, cognitive behavioral therapy, and contingency management. Their findings suggest that a combination of these three modalities produces the best abstinence outcomes, although abstinence rates remain modest and decline after treatment. More recently, pharmacotherapy trials have been conducted as adjunctive interventions to psychosocial treatment. N‐acetylcysteine and gabapentin are two of the most promising medications, although no pharmacologic treatment has emerged as clearly efficacious. In this review, we provide a detailed summary of clinical trials that evaluated psychotherapy and pharmacotherapy for treating CUD and discuss emerging areas of clinical research and cannabis‐specific barriers to treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Motivational Interviewing: Helping People Change
Tober, G. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt010 · Cited by 4,268
Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors
Washton, A. M. (1986) · Journal of Studies on Alcohol · doi:10.15288/jsa.1986.47.260 · Cited by 2,527
(2013) · Cited by 2,393
(1997) · Journal of Studies on Alcohol · doi:10.15288/jsa.1997.58.7 · Cited by 1,905
Anthony, J. C., Warner, L. A., & Kessler, R. C. (1994) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.2.3.244 · Cited by 1,341
A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111851 · Cited by 1,287
Cannabis use and mental health in young people: cohort study.
Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M., & Hall, W. (2002) · BMJ · doi:10.1136/bmj.325.7374.1195 · Cited by 997
Gender differences in substance use disorders
Brady, K. T., & Randall, C. L. (1999) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70074-5 · Cited by 910
The Cannabis Youth Treatment (CYT) Study: Main findings from two randomized trials
Dennis, M., Godley, S. H., Diamond, G., Tims, F. M., Babor, T., Donaldson, J., Liddle, H., Titus, J. C., Kaminer, Y., Webb, C., et al. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2003.09.005 · Cited by 777 · cited 1×
“The Cannabis Youth Treatment study is another large clinical trial (600 participants) that examined the efficacy and cost-effectiveness of five short-term psychotherapy treatments for adolescents with CUD across four study sites and two related clinical trials.(34) Trial 1 compared a 5-session MET/CBT treatment (MET/…”
BackgroundComparison of extended versus brief treatments for marijuana use.
Stephens, R. S., Roffman, R. A., & Curtin, L. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.5.898 · Cited by 711 · cited 1×
“The authors conducted a subsequent study examining extended versus brief interventions and included a delayed treatment control group for comparison.(18) A total of 291 adult treatment-seeking marijuana users were randomly assigned to a 14-session relapse prevention support group (RPSG), a 2-session individual assessm…”
MethodPsychiatric Diagnoses of Treatment-Seeking Cocaine Abusers
Rounsaville, B. J. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810250045005 · Cited by 605
Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH Three‐Year Drinking Outcomes
Project MATCH Research Group (1998) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1998.tb03912.x · Cited by 578
Enhancing motivation for change in problem drinking: a controlled comparison of two therapist styles
Miller, W. R., Benefield, R. G., & Tonigan, J. S. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.3.455 · Cited by 566
Cannabis use and later life outcomes
Fergusson, D. M., & Boden, J. M. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02221.x · Cited by 526
Cannabis use disorders in the USA: prevalence, correlates and co-morbidity
STINSON, F. S., RUAN, W. J., PICKERING, R., & GRANT, B. F. (2006) · Psychological Medicine · doi:10.1017/s0033291706008361 · Cited by 422
Diagnosis and Symptoms of Depression in Opiate Addicts: Course and Relationship to Treatment Outcome
Rounsaville, B. J. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290020021004 · Cited by 410
Gender differences in substance use disorders
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.11.1707 · Cited by 377
FLORY, K., LYNAM, D., MILICH, R., LEUKEFELD, C., & CLAYTON, R. (2004) · Development and Psychopathology · doi:10.1017/s0954579404044475 · Cited by 376
The cannabis withdrawal syndrome
Budney, A. J., & Hughes, J. R. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000218592.00689.e5 · Cited by 349
Miller, W. R., Sovereign, R. G., & Krege, B. (1988) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s0141347300014129 · Cited by 334
A randomized controlled trial of brief cognitive–behavioral interventions for cannabis use disorder
Copeland, J., Swift, W., Roffman, R., & Stephens, R. (2001) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(01)00179-9 · Cited by 322
Budney, A. J., Higgins, S. T., Radonovich, K. J., & Novy, P. L. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.6.1051 · Cited by 318
Brief treatments for cannabis dependence: Findings from a randomized multisite trial
Babor, T. F., & The Marijuana Treatment Project Research Group (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.3.455 · Cited by 313
Gone to Pot – A Review of the Association between Cannabis and Psychosis
Radhakrishnan, R., Wilkinson, S. T., & D’Souza, D. C. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00054 · Cited by 310
Crane, N. A., Schuster, R. M., Fusar-Poli, P., & Gonzalez, R. (2013) · Neuropsychology Review · doi:10.1007/s11065-012-9222-1 · Cited by 309
A Double-Blind Randomized Controlled Trial of N -Acetylcysteine in Cannabis-Dependent Adolescents
Gray, K. M., Carpenter, M. J., Baker, N. L., DeSantis, S. M., Kryway, E., Hartwell, K. J., McRae-Clark, A. L., & Brady, K. T. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010055 · Cited by 306
Self-citationBudney, A. J., Moore, B. A., Rocha, H. L., & Higgins, S. T. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.4.2.307 · Cited by 290 · cited 1×
“A follow-up study examined the longer term effects of an abstinence-based voucher program and tested whether CBT enhanced the effect.(10) Assessments of substance use and related problems were conducted at baseline, end of treatment, and every 3 months through 1 year after treatment.”
BackgroundMiller, W. R., Benefield, R. G., & Tonigan, J. S. (2001) · Helping skills: The empirical foundation. · doi:10.1037/10412-014 · Cited by 288
Treating adult marijuana dependence: A test of the relapse prevention model.
Stephens, R. S., Roffman, R. A., & Simpson, E. E. (1994) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.62.1.92 · Cited by 270
Kay‐Lambkin, F. J., Baker, A. L., Lewin, T. J., & Carr, V. J. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02444.x · Cited by 269
Plescia, F., Brancato, A., Marino, R. A. M., Vita, C., Navarra, M., & Cannizzaro, C. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00138 · Cited by 266
Marijuana Withdrawal in Humans: Effects of Oral THC or Divalproex
Haney, M., Hart, C. L., Vosburg, S. K., Nasser, J., Bennett, A., Zubaran, C., & Foltin, R. W. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300310 · Cited by 264 · cited 1×
“Oral THC 10 mg administered 5 times/day decreased both withdrawal symptoms and cannabis craving in an inpatient laboratory study.(51) An outpatient trial found oral THC at doses of 10 mg 3 times/day and 30 mg 3 times/day to be effective in suppressing cannabis withdrawal TREATMENT OF CANNABIS USE DISORDER Sherman and…”
BackgroundBuspirone Treatment of Anxious Alcoholics: A Placebo-Controlled Trial
Kranzler, H. R. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950090052008 · Cited by 248
Mason, B. J., Crean, R., Goodell, V., Light, J. M., Quello, S., Shadan, F., Buffkins, K., Kyle, M., Adusumalli, M., Begovic, A., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.14 · Cited by 242 · cited 1×
“The anticonvulsant gabapentin was evaluated as a treatment in 50 cannabis-dependent individuals.(68) Although the sample size was small and attrition relatively high with 18 participants completing the 8-week trial, gabapentin treatment resulted in significantly less cannabis use by both self-report and urine toxicolo…”
MethodLevin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.12.010 · Cited by 232
Carroll, K. M., Easton, C. J., Nich, C., Hunkele, K. A., Neavins, T. M., Sinha, R., Ford, H. L., Vitolo, S. A., Doebrick, C. A., & Rounsaville, B. J. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.5.955 · Cited by 214 · cited 1×
“In a randomized clinical trial of 136 individuals referred by the criminal justice system for treatment of marijuana dependence, a group of authors examined the effects of drug counseling (DC) and CM when added to an MET/CBT intervention.(36) The study compared four treatment conditions: MET/ CBT alone, MET/CBT plus C…”
MethodLiddle, H. A., Dakof, G. A., Turner, R. M., Henderson, C. E., & Greenbaum, P. E. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02274.x · Cited by 211 · cited 2×
“A randomized trial compared MDFT with CBT and assigned 224 substance-abusing adolescents (and their parents in the case of MDFT) to receive individual CBT or MDFT.37 Both interventions reduced adolescent cannabis consumption, but there were no significant between-group differences.”
MethodPotential Role of N-Acetylcysteine in the Management of Substance Use Disorders
McClure, E. A., Gipson, C. D., Malcolm, R. J., Kalivas, P. W., & Gray, K. M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0142-x · Cited by 193
Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms
Budney, A. J., Vandrey, R. G., Hughes, J. R., Moore, B. A., & Bahrenburg, B. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.014 · Cited by 180
van der Pol, P., Liebregts, N., de Graaf, R., Korf, D. J., van den Brink, W., & van Laar, M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.06.009 · Cited by 180
Carroll, K. M., Kiluk, B. D., Nich, C., Gordon, M. A., Portnoy, G. A., Marino, D. R., & Ball, S. A. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070987 · Cited by 177
Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse
Haney, M., Hart, C. L., Vosburg, S. K., Comer, S. D., Reed, S. C., & Foltin, R. W. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1020-8 · Cited by 174 · cited 2×
“Of note, a follow-up human laboratory study found that the combination of oral THC and lofexidine, an a2-receptor agonist, may have synergistic effects for improving measures of withdrawal symptomatology as well as decreasing relapse in a laboratory model.(53) The synthetic cannabinoid nabilone has also shown promise…”
BackgroundAbstinence rates following behavioral treatments for marijuana dependence
Kadden, R. M., Litt, M. D., Kabela-Cormier, E., & Petry, N. M. (2007) · Addictive Behaviors · doi:10.1016/j.addbeh.2006.08.009 · Cited by 173 · cited 1×
“A randomized clinical trial comparing MET/CBT, MET/CBT/CM, CM only, and case management control among 240 marijuana-dependent individuals resulted in similar patterns.(11) The CMonly condition had the highest abstinence rates at the end of treatment, and the MET/CBT/CM condition showed the greatest durability of effec…”
Interactive voice response: Review of studies 1989–2000
Corkrey, R., & Parkinson, L. (2002) · Behavoir research methods, instruments & computers · doi:10.3758/bf03195462 · Cited by 171
Nunes, E. V., Quitkin, F. M., Donovan, S. J., Deliyannides, D., Ocepek-Welikson, K., Koenig, T., Brady, R., McGrath, P. J., & Woody, G. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.2.153 · Cited by 164
Pharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156
Addictive Behaviors: Prevention and Early Intervention
Babor, T. F. (1992) · Journal of Studies on Alcohol · doi:10.15288/jsa.1992.53.396 · Cited by 153
The adolescent cannabis check-up: Randomized trial of a brief intervention for young cannabis users
Martin, G., & Copeland, J. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.07.004 · Cited by 152 · cited 2×
“Two authors developed the Adolescent Cannabis Check-Up (ACCU), a brief two-session motivational intervention modeled after the MCU.(26) In a randomized controlled trial, the authors compared the ACCU with a delayed treatment control DTC group among 40 non–treatmentseeking adolescents.”
MethodFidelity to Motivational Interviewing and subsequent cannabis cessation among adolescents
McCambridge, J., Day, M., Thomas, B. A., & Strang, J. (2011) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.03.002 · Cited by 150 · cited 1×
“In secondary analysis, the authors found that after controlling for practitioner effects, MI spirit and proportion of complex reflections independently predicted abstinence at 3-month follow-up.(29) No other aspects of MI predicted cannabis cessation.”
BackgroundComorbidity in mania at first hospitalization
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.4.554 · Cited by 144
Effectiveness of a self-guided web-based cannabis treatment program: randomized controlled trial
Rooke, S., Copeland, J., Norberg, M., Hine, D., & McCambridge, J. (2013) · Journal of Medical Internet Research · doi:10.2196/jmir.2256 · Cited by 141
Immediate antecedents of marijuana use: An analysis from ecological momentary assessment
Buckner, J. D., Crosby, R. D., Silgado, J., Wonderlich, S. A., & Schmidt, N. B. (2012) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2011.09.010 · Cited by 139
Nabilone Decreases Marijuana Withdrawal and a Laboratory Measure of Marijuana Relapse
Haney, M., Cooper, Z. D., Bedi, G., Vosburg, S. K., Comer, S. D., & Foltin, R. W. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.54 · Cited by 139 · cited 1×
“The synthetic cannabinoid nabilone has also shown promise in laboratory evaluation, significantly attenuating withdrawal symptoms such as irritability and sleep disruptions while also reducing relapse behavior.(54) Anticonvulsants and Mood Stabilizers The mood stabilizer divalproex was shown to decrease cannabis cravi…”
BackgroundBupropion SR worsens mood during marijuana withdrawal in humans
Haney, M., Ward, A. S., Comer, S. D., Hart, C. L., Foltin, R. W., & Fischman, M. W. (2001) · Psychopharmacology · doi:10.1007/s002130000657 · Cited by 135 · cited 1×
“Antidepressants An initial study evaluated the effects of sustained-release bupropion in non–treatment-seeking heavy cannabis smokers.(47) During a 12-day inpatient abstinence period, participants were randomized to receive bupropion or placebo.”
BackgroundKay‐Lambkin, F. J., Baker, A. L., Kelly, B., & Lewin, T. J. (2011) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb03265.x · Cited by 128
Searles, J. S., Helzer, J. E., Rose, G. L., & Badger, G. J. (2002) · Journal of Studies on Alcohol · doi:10.15288/jsa.2002.63.352 · Cited by 122
The Check-up: A model for early intervention in addictive behaviors.
Miller, W. R., & Sovereign, R. G. (1989) · Cited by 118
Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal
Vandrey, R., Smith, M. T., McCann, U. D., Budney, A. J., & Curran, E. M. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.01.003 · Cited by 116 · cited 1×
“Sedative-Hypnotics The utility of extended-release zolpidem in targeting cannabis abstinence–induced sleep disruptions was evaluated.(57) Zolpidem attenuated the effects of cannabis abstinence on sleep architecture and normalized sleep efficiency scores but did not affect sleep latency.”
Background(1995) · PubMed · Cited by 115
Levin, F. R., McDowell, D., Evans, S. M., Nunes, E., Akerele, E., Donovan, S., & Vosburg, S. K. (2004) · The American Journal on Addictions · doi:10.1080/10550490490265280 · Cited by 113 · cited 1×
“Anticonvulsants and Mood Stabilizers A randomized double-blind, placebo-controlled crossover study of the mood stabilizer divalproex in 25 cannabis-dependent adults was conducted; no significant effects of divalproex on psychological or cannabis use outcomes were observed.(67) The anticonvulsant gabapentin was evaluat…”
BackgroundHendriks, V. M., van der Schee, E., & Blanken, P. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.05.021 · Cited by 113
Budney, A. J., Radonovich, K. J., Higgins, S. T., & Wong, C. J. (1998) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.6.4.419 · Cited by 112
Therapeutic Interactive Voice Response for chronic pain reduction and relapse prevention
Naylor, M. R., Keefe, F. J., Brigidi, B., Naud, S., & Helzer, J. E. (2008) · Pain · doi:10.1016/j.pain.2007.11.001 · Cited by 111
N‐Acetylcysteine (NAC) in Young Marijuana Users: An Open‐Label Pilot Study
Gray, K. M., Watson, N. L., Carpenter, M. J., & LaRowe, S. D. (2010) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2009.00027.x · Cited by 109 · cited 1×
“An open-label trial of NAC in 24 young (18–21 yrs) cannabis users demonstrated reductions in self-report of cannabis use and cannabis craving.(69) A followup larger placebo-controlled study conducted in 116 participants showed that participants receiving NAC, when paired with brief counseling and CM to promote abstine…”
MethodBarriers and facilitators to cannabis treatment
GATES, P., COPELAND, J., SWIFT, W., & MARTIN, G. (2012) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2011.00313.x · Cited by 109
McCambridge, J., Slym, R. L., & Strang, J. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02331.x · Cited by 107
Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.
Cornelius, J. R., Bukstein, O. G., Douaihy, A. B., Clark, D. B., Chung, T. A., Daley, D. C., Wood, D. S., & Brown, S. J. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.05.010 · Cited by 105 · cited 1×
“However, a trial in adolescents and young adults with comorbid major depression and CUD did not find a significant effect of fluoxetine on cannabis-related outcomes.(80) A recent trial examined the utility of extended-release venlafaxine combined with CBT for co-occurring cannabis dependence and depressive disorders.”
BackgroundMarsch, L. A., Carroll, K. M., & Kiluk, B. D. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2013.08.010 · Cited by 105 · cited 1×
“These computer and Internet-based treatments seek to improve service access, reduce training and delivery costs, ensure treatment fidelity, and enhance existing evidence-based approaches.(83) Several studies have shown promising initial results.”
BackgroundA controlled trial of an Internet-based intervention program for cannabis users
Tossmann, D. H.-P., Jonas, B., Tensil, M.-D., Lang, P., & Strüber, E. (2011) · Cyberpsychology Behavior and Social Networking · doi:10.1089/cyber.2010.0506 · Cited by 99
Facilitators and barriers in treatment seeking for cannabis dependence
van der Pol, P., Liebregts, N., de Graaf, R., Korf, D. J., van den Brink, W., & van Laar, M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.08.011 · Cited by 95
Epidemiology of substance use disorders in women
Greenfield, S. F., Manwani, S. G., & Nargiso, J. E. (2003) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(03)00072-x · Cited by 95
The Marijuana Check-up: promoting change in ambivalent marijuana users.
Stephens, R. S., Roffman, R. A., Fearer, S. A., Williams, C., & Burke, R. S. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01821.x · Cited by 94
Nefazodone decreases anxiety during marijuana withdrawal in humans
Haney, M., Hart, C., Ward, A., & Foltin, R. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1210-3 · Cited by 94 · cited 1×
“Nefazodone has also been evaluated in an inpatient laboratory model.(49) Nefazodone decreased reports of anxiety and muscle pain during cannabis withdrawal but did not reduce other withdrawal symptoms such as irritability and difficulty sleeping.”
BackgroundCarroll, K. M., Nich, C., LaPaglia, D. M., Peters, E. N., Easton, C. J., & Petry, N. M. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03877.x · Cited by 91
McRae‐Clark, A. L., Carter, R. E., Killeen, T. K., Carpenter, M. J., White, K. G., & Brady, K. T. (2010) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2010.00076.x · Cited by 91 · cited 1×
“Finally, an evaluation of atomoxetine combined with MET on the symptoms of attention deficit/hyperactivity disorder (ADHD) and cannabis use in cannabis-dependent adults found limited improvement in ADHD measurements but no improvement on cannabis use outcomes.(82) Table 4 summarizes the clinical trials of pharmacother…”
Self-citationLevin, F. R., Mariani, J., Brooks, D. J., Pavlicova, M., Nunes, E. V., Agosti, V., Bisaga, A., Sullivan, M. A., & Carpenter, K. M. (2013) · Addiction · doi:10.1111/add.12108 · Cited by 89
Carpenter, K. M., McDowell, D., Brooks, D. J., Cheng, W. Y., & Levin, F. R. (2009) · The American Journal on Addictions · doi:10.1080/10550490802408936 · Cited by 89 · cited 1×
“Antidepressants and Anxiolytics Nefazodone and sustained-release bupropion were evaluated in a placebo-controlled trial of cannabis-dependent adults; neither medication had a significant effect on cannabis use or cannabis withdrawal symptoms.(60) A recent study of escitalopram in an adult population also failed to fin…”
BackgroundA placebo-controlled trial of buspirone for the treatment of marijuana dependence
McRae-Clark, A. L., Carter, R. E., Killeen, T. K., Carpenter, M. J., Wahlquist, A. E., Simpson, S. A., & Brady, K. T. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.06.022 · Cited by 87
Self-citationMotivational and mindfulness intervention for young adult female marijuana users
de Dios, M. A., Herman, D. S., Britton, W. B., Hagerty, C. E., Anderson, B. J., & Stein, M. D. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.08.001 · Cited by 86 · cited 1×
“In light of growing evidence demonstrating health benefits of mindfulness meditation, one study sought to augment a traditional motivational intervention for cannabis-using women aged 18–29 years by adding a mindfulness component.(39) This pilot study randomly assigned 34 women to either motivational interviewing plus…”
BackgroundSocial anxiety and cannabis use: An analysis from ecological momentary assessment
Buckner, J. D., Crosby, R. D., Wonderlich, S. A., & Schmidt, N. B. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2011.12.006 · Cited by 86
Self-change: A pathway to cannabis abuse resolution
Ellingstad, T. P., Sobell, L. C., Sobell, M. B., Eickleberry, L. G., & Golden, C. J. (2005) · Addictive Behaviors · doi:10.1016/j.addbeh.2005.05.033 · Cited by 79
Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse
Haney, M., Hart, C. L., Vosburg, S. K., Comer, S. D., Reed, S. C., Cooper, Z. D., & Foltin, R. W. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1888-6 · Cited by 78 · cited 2×
“Other Medication Classes The c-aminobutyric acid-B receptor agonist, baclofen, reduced cannabis craving during an active smoking paradigm but had limited impact on cannabis withdrawal symptoms in an inpatient laboratory evaluation.(50) Baclofen also did not decrease measures of cannabis relapse.”
BackgroundThe Marijuana Check‐up: reaching users who are ambivalent about change
Stephens, R. S., Roffman, R. A., Fearer, S. A., Williams, C., Picciano, J. F., & Burke, R. S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00832.x · Cited by 78
Computer-assisted behavioral therapy and contingency management for cannabis use disorder.
Budney, A. J., Stanger, C., Tilford, J. M., Scherer, E. B., Brown, P. C., Li, Z., Li, Z., & Walker, D. D. (2015) · Psychology of Addictive Behaviors · doi:10.1037/adb0000078 · Cited by 72
Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial
McRae-Clark, A. L., Baker, N. L., Gray, K. M., Killeen, T. K., Wagner, A. M., Brady, K. T., DeVane, C. L., & Norton, J. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.08.013 · Cited by 72
Self-citationLitt, M. D., Kadden, R. M., & Petry, N. M. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.08.011 · Cited by 71 · cited 1×
“One study examined a behavioral treatment designed to enhance coping self-efficacy by comparing the addition of two different CM interventions with standard MET/ CBT in a randomized clinical trial.(15) Participants received either MET/CBT + CM for homework completion, MET/CBT + CM for abstinence, or case management co…”
MethodShrier, L. A., Rhoads, A. M., Burke, P. J., Walls, C. E., & Blood, E. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.09.028 · Cited by 71
An initial trial of a computerized behavioral intervention for cannabis use disorder
Budney, A. J., Fearer, S., Walker, D. D., Stanger, C., Thostenson, J., Grabinski, M., & Bickel, W. K. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.10.014 · Cited by 70
Cooper, Z. D., Foltin, R. W., Hart, C. L., Vosburg, S. K., Comer, S. D., & Haney, M. (2013) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00461.x · Cited by 63 · cited 1×
“Quetiapine, an atypical antipsychotic, improved sleep quality and appetite during cannabis withdrawal but increased cannabis craving and relapse.(58) As discussed earlier, lofexidine did not demonstrate utility on its own for cannabis withdrawal; however, the combination of lofexidine and oral THC significantly amelio…”
BackgroundChoosing a behavioral therapy platform for pharmacotherapy of substance users
Carroll, K. M., Kosten, T. R., & Rounsaville, B. J. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.02.007 · Cited by 62
A brief marijuana intervention for non-treatment-seeking young adult women.
Stein, M. D., Hagerty, C. E., Herman, D. S., Phipps, M. G., & Anderson, B. J. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.11.001 · Cited by 61 · cited 1×
“efficacy of a brief MI intervention among non– treatment-seeking women aged 18–24 years, 332 participants were randomized into a two-session MI intervention or an assessment only (AO) control.(33) At the 3-month follow-up, MI participants showed a significant reduction in days of use compared with AO.”
MethodFluoxetine versus placebo for the marijuana use of depressed alcoholics
Cornelius, J. R., Salloum, I. M., Haskett, R. F., Ehler, J. G., Jarrett, P. J., Thase, M. E., & Perel, J. M. (1999) · Addictive Behaviors · doi:10.1016/s0306-4603(98)00050-1 · Cited by 56 · cited 1×
“A secondary analysis found that fluoxetine treatment significantly reduced cannabis use in depressed alcohol-dependent adults.(79) However, a trial in adolescents and young adults with comorbid major depression and CUD did not find a significant effect of fluoxetine on cannabis-related outcomes.”
BackgroundWeinstein, A. M., Miller, H., Bluvstein, I., Rapoport, E., Schreiber, S., Bar-Hamburger, R., & Bloch, M. (2014) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2013.819362 · Cited by 53 · cited 1×
“A recent study of escitalopram in an adult population also failed to find a positive effect of treatment on abstinence or withdrawal outcomes.(61) Buspirone, a nonbenzodiazepine anxiolytic, showed limited preliminary evidence as a potential treatment for CUDs.”
BackgroundLithium carbonate in the management of cannabis withdrawal in humans: an open-label study
Winstock, A., Lea, T., & Copeland, J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089584 · Cited by 52
Johnston, J., Lintzeris, N., Allsop, D. J., Suraev, A. S., Booth, J., Carson, D. S., Helliwell, D., WINSTOCK, A. R., & McGregor, I. S. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3611-5 · Cited by 47 · cited 1×
“Although a small open-label evaluation suggested some utility for lithium carbonate for management of cannabis withdrawal,(55) a recent randomized placebo-controlled trial conducted in an inpatient setting failed to show an effect of lithium treatment on withdrawal symptoms.(56) Sedative-Hypnotics The utility of exten…”
Backgroundde Gee, E. A., Verdurmen, J. E. E., Bransen, E., de Jonge, J. M., & Schippers, G. M. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.05.001 · Cited by 42 · cited 1×
“A larger replication study conducted in the Netherlands did not find a significant treatment effect of ACCU over time.(27) However, baseline level of use appeared to moderate the effect of treatment on marijuana use; heavy users (who smoked more than 14 joints per week) receiving the MET intervention showed greater re…”
MethodPenetar, D. M., Looby, A. R., Ryan, E. T., Maywalt, M. A., & Lukas, S. E. (2012) · Substance Abuse Research and Treatment · doi:10.4137/sart.s9706 · Cited by 42 · cited 1×
“A small recent preliminary outpatient evaluation of bupropion reported more promising results; however, the sample size was small (nine participants).(48) Using a paradigm similar to that used for cigarette smoking cessation, withdrawal symptoms were greater in placebo-treated participants, and cannabis craving increa…”
ResultNuijten, M., Blanken, P., van den Brink, W., & Hendriks, V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.02.024 · Cited by 38
Buspirone for Treatment of Marijuana Dependence: A Pilot Study
McRae‐Clark, A. L., Brady, K. T., & Carter, R. E. (2006) · American Journal on Addictions · doi:10.1080/10550490600860635 · Cited by 36
Self-citationA 2.5 year follow-up of treatment retention and reentry among opioid addicts
Kosten, T. A. (1986) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(86)90019-x · Cited by 31
van der Pol, P., Liebregts, N., de Graaf, R., Korf, D. J., van den Brink, W., & van Laar, M. (2011) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.345 · Cited by 31
Efficacy of automated telephone continuing care following outpatient therapy for alcohol dependence
Rose, G. L., Skelly, J. M., Badger, G. J., Ferraro, T. A., & Helzer, J. E. (2014) · Addictive Behaviors · doi:10.1016/j.addbeh.2014.10.022 · Cited by 25
Maintenance Check-ups Following Treatment for Cannabis Dependence
Walker, D. D., Stephens, R. S., Towe, S. L., Banes, K. E., & Roffman, R. A. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.03.006 · Cited by 23 · cited 1×
“Toward enhancing long-term outcomes, a recent study examined whether adding posttreatment MET checkups would augment standard MET/CBT treatment.(35) The authors randomized 74 participants into either MET/CBT with maintenance checkups (MCU) or MET/CBT with no checkups (NCU).”
BackgroundKaminer, Y. (1992) · American Journal on Addictions · doi:10.1111/j.1521-0391.1992.tb00003.x · Cited by 21
Quetiapine for the treatment of cocaine use disorder
Tapp, A. M., Wood, A. E., Kennedy, A., Sylvers, P. D., Kilzieh, N., & Saxon, A. J. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.12.037 · Cited by 16
Cited by
Degenhardt, L., Glantz, M., Evans‐Lacko, S., Sadikova, E., Sampson, N., Thornicroft, G., Aguilar‐Gaxiola, S., Al‐Hamzawi, A., Alonso, J., Helena Andrade, L., et al. (2017) · World Psychiatry · doi:10.1002/wps.20457 · Cited by 267
Pharmacotherapies for cannabis dependence
Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub3 · Cited by 96
Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms
DeVuono, M. V., & Parker, L. A. (2020) · Cannabis & Cannabinoid Research · doi:10.1089/can.2019.0059 · Cited by 87
Meta-review on the efficacy of psychological therapies for the treatment of substance use disorders
Dellazizzo, L., Potvin, S., Giguère, S., Landry, C., Léveillé, N., & Dumais, A. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115318 · Cited by 55
Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study
Azhari, N., Hu, H., O’Malley, K. Y., Blocker, M. E., Levin, F. R., & Dakwar, E. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1808982 · Cited by 48
Metadata
- Authors
- Sherman, B. J., & McRae‐Clark, A. L.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2016-05
- Volume
- 36
- Issue
- 5
- Pages
- 511-535
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2319647004
- Cited by
- 208
- References
- 106
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.